Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 7, ...
The most common side effects with Kesimpta (which may affect more than 1 in 10 people) are upper respiratory tract infections (nose and throat infections), urinary tract infections (infections of the structures that carry urine), reactions at the site of …